{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:17:26Z","timestamp":1792700246587,"version":"4.5.0"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.canlet.2022.216043","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T02:10:18Z","timestamp":1672107018000},"page":"216043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"special_numbering":"C","title":["CD8+ T cell exhaustion and cancer immunotherapy"],"prefix":"10.1016","volume":"559","author":[{"given":"Qingda","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"Ca - Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00005-014-0293-y","article-title":"Heterogeneity in the differentiation and function of CD8+ T cells","volume":"62","author":"Mittr\u00fccker","year":"2014","journal-title":"Arch. Immunol. Ther. Exp."},{"issue":"8","key":"10.1016\/j.canlet.2022.216043_bib3","first-page":"4165","article-title":"The prognostic significance of the tumor-infiltrating programmed cell death-1+ to CD8+ lymphocyte ratio in patients with colorectal cancer","volume":"37","author":"Shibutani","year":"2017","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.canlet.2022.216043_bib4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/SLA.0000000000002985","article-title":"Prognostic nutritional index, tumor-infiltrating lymphocytes, and prognosis in patients with esophageal cancer","volume":"271","author":"Okadome","year":"2020","journal-title":"Ann. Surg."},{"issue":"8","key":"10.1016\/j.canlet.2022.216043_bib5","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/15384047.2020.1856756","article-title":"Epigenetic modulation of FBW7\/Mcl-1 pathway for lung cancer therapy","volume":"22","author":"Kim","year":"2021","journal-title":"Cancer Biol. Ther."},{"issue":"2","key":"10.1016\/j.canlet.2022.216043_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","article-title":"The emerging role of epigenetic therapeutics in immuno-oncology","volume":"17","author":"Topper","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2022.216043_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","article-title":"Tolerance and exhaustion: defining mechanisms of T cell dysfunction","volume":"35","author":"Schietinger","year":"2014","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nri3790","article-title":"Clinical blockade of PD1 and LAG3\u2014potential mechanisms of action","volume":"15","author":"Nguyen","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"6230","key":"10.1016\/j.canlet.2022.216043_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.canlet.2022.216043_bib11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/10245332.2018.1486357","article-title":"PD-1 blockade potentially enhances adoptive cytotoxic T cell potency in a human acute myeloid leukaemia animal model","volume":"23","author":"Deng","year":"2018","journal-title":"Hematology"},{"issue":"17","key":"10.1016\/j.canlet.2022.216043_bib12","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"13","key":"10.1016\/j.canlet.2022.216043_bib13","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2022.216043_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"17","key":"10.1016\/j.canlet.2022.216043_bib15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"21","key":"10.1016\/j.canlet.2022.216043_bib16","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1158\/0008-5472.CAN-20-0285","article-title":"A\u00a0DNA hypomethylating drug alters the tumor microenvironment and improves the effectiveness of immune checkpoint inhibitors in a mouse model of pancreatic cancer","volume":"80","author":"Gonda","year":"2020","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2022.216043_bib17","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/hep.31921","article-title":"Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti\u2013programmed cell death-1 in HCC","volume":"74","author":"Yi","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.canlet.2022.216043_bib18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J.\u00a0Hepatol."},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib19","first-page":"1","article-title":"DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer","volume":"9","author":"Luo","year":"2018","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.canlet.2022.216043_bib20","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.cell.2018.08.048","article-title":"Evolutionary pressure against MHC class II binding cancer mutations","volume":"175","author":"Pyke","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.canlet.2022.216043_bib21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/2326-6066.CIR-18-0283","article-title":"A\u00a0synthetic DNA, multi-neoantigen vaccine drives predominately MHC class I CD8+ T-cell responses, impacting tumor challenge","volume":"7","author":"Duperret","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.canlet.2022.216043_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1152\/advan.00066.2013","article-title":"T\u00a0cell responses: naive to memory and everything in between","volume":"37","author":"Pennock","year":"2013","journal-title":"Adv. Physiol. Educ."},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib23","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1128\/MCB.15.6.3197","article-title":"Regulation of interleukin 2 gene expression by CD28 costimulation in mouse T-cell clones: both nuclear and cytoplasmic RNAs are regulated with complex kinetics","volume":"15","author":"Umlauf","year":"1995","journal-title":"Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.canlet.2022.216043_bib24","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.ymthe.2021.01.021","article-title":"The CD39(+) HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8(+) T cells exhibit potent anti-HCC activity","volume":"29","author":"Zou","year":"2021","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.canlet.2022.216043_bib25","first-page":"105","article-title":"Interferon gamma stimulates cellular maturation of dendritic cell line DC2. 4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity","volume":"4","author":"He","year":"2007","journal-title":"Cell. Mol. Immunol."},{"issue":"4","key":"10.1016\/j.canlet.2022.216043_bib26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-3083.2008.02083.x","article-title":"Appropriate timing of CD40 ligation for RNA-pulsed DCs to induce antitumor immunity","volume":"67","author":"Miura","year":"2008","journal-title":"Scand. J. Immunol."},{"issue":"4","key":"10.1016\/j.canlet.2022.216043_bib27","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1039\/C8BM01556B","article-title":"Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells","volume":"7","author":"Xie","year":"2019","journal-title":"Biomater. Sci."},{"issue":"22","key":"10.1016\/j.canlet.2022.216043_bib28","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1182\/blood-2008-11-188458","article-title":"Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8+ effector versus central memory T-cell fates","volume":"113","author":"Ramos","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.canlet.2022.216043_bib29","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.4049\/jimmunol.181.4.2277","article-title":"Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression","volume":"181","author":"Xiao","year":"2008","journal-title":"J.\u00a0Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-020-00897-z","article-title":"Th17 cells inhibit CD8(+) T cell migration by systematically downregulating CXCR3 expression via IL-17A\/STAT3 in advanced-stage colorectal cancer patients","volume":"13","author":"Wang","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2022.216043_bib31","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.4049\/jimmunol.1502376","article-title":"Chemoattractant receptors BLT1 and CXCR3 regulate antitumor immunity by facilitating CD8+ T cell migration into tumors","volume":"197","author":"Chheda","year":"2016","journal-title":"J.\u00a0Immunol."},{"issue":"5","key":"10.1016\/j.canlet.2022.216043_bib32","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1158\/2326-6066.CIR-18-0517","article-title":"A\u00a0transcriptionally distinct CXCL13(+)CD103(+)CD8(+) T-cell population is associated with B-cell recruitment and neoantigen load in human cancer","volume":"7","author":"Workel","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"10.1016\/j.canlet.2022.216043_bib33","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.18632\/oncotarget.3205","article-title":"Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration","volume":"6","author":"Zumwalt","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.canlet.2022.216043_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317699133","article-title":"The role of sphingosine-1-phosphate in the tumor microenvironment and its clinical implications","volume":"39","author":"Nakajima","year":"2017","journal-title":"Tumour Biol J Int Soc Oncodevelopmental Biol Med"},{"issue":"13","key":"10.1016\/j.canlet.2022.216043_bib35","article-title":"Trajectory and functional analysis of PD-1(high) CD4(+)CD8(+) T cells in hepatocellular carcinoma by single-cell cytometry and transcriptome sequencing","volume":"7","author":"Zheng","year":"2020","journal-title":"Adv Sci (Weinheim, Baden-Wurttemberg, Ger."},{"issue":"3","key":"10.1016\/j.canlet.2022.216043_bib36","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1002\/ctm2.133","article-title":"Analysis of single-cell RNAseq identifies transitional states of T cells associated with hepatocellular carcinoma","volume":"10","author":"Yang","year":"2020","journal-title":"Clin. Transl. Med."},{"issue":"7685","key":"10.1016\/j.canlet.2022.216043_bib37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nature25144","article-title":"Effector CD8 T cells dedifferentiate into long-lived memory cells","volume":"552","author":"Youngblood","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.canlet.2022.216043_bib38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nri3442","article-title":"The integration of T cell migration, differentiation and function","volume":"13","author":"Masopust","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.canlet.2022.216043_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274494","article-title":"Transcriptome analysis of Homo sapiens and Mus musculus reveals mechanisms of CD8+ T cell exhaustion caused by different factors","volume":"17","author":"Zhang","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.canlet.2022.216043_bib40","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.canlet.2022.216043_bib41","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib43","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De Novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.canlet.2022.216043_bib44","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.1128\/JVI.00889-12","article-title":"Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection","volume":"86","author":"Angelosanto","year":"2012","journal-title":"J.\u00a0Virol."},{"issue":"2","key":"10.1016\/j.canlet.2022.216043_bib45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","article-title":"The transcription factor NFAT promotes exhaustion of activated CD8+ T cells","volume":"42","author":"Martinez","year":"2015","journal-title":"Immunity"},{"issue":"13","key":"10.1016\/j.canlet.2022.216043_bib46","doi-asserted-by":"crossref","first-page":"E2776","DOI":"10.1073\/pnas.1620498114","article-title":"Exhaustion-associated regulatory regions in CD8(+) tumor-infiltrating T cells","volume":"114","author":"Mognol","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.canlet.2022.216043_bib47","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.canlet.2022.216043_bib48","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4049\/jimmunol.1601301","article-title":"Endogenous Nur77 is a specific indicator of antigen receptor signaling in human T and B cells","volume":"198","author":"Ashouri","year":"2017","journal-title":"J.\u00a0Immunol."},{"issue":"7764","key":"10.1016\/j.canlet.2022.216043_bib49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib50","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.immuni.2017.11.021","article-title":"Transcription factor IRF4 promotes CD8(+) T cell exhaustion and limits the development of memory-like T cells during chronic infection","volume":"47","author":"Man","year":"2017","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib51","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.canlet.2022.216043_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100828","article-title":"Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer","volume":"13","author":"Cohen","year":"2020","journal-title":"Transl Oncol"},{"issue":"11","key":"10.1016\/j.canlet.2022.216043_bib53","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-15-0036","article-title":"Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies","volume":"3","author":"Hossain","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.canlet.2022.216043_bib54","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.canlet.2022.216043_bib55","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell-derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"issue":"4 Pt 1","key":"10.1016\/j.canlet.2022.216043_bib56","doi-asserted-by":"crossref","first-page":"C761","DOI":"10.1152\/ajpcell.1993.264.4.C761","article-title":"Transport of lactate and other monocarboxylates across mammalian plasma membranes","volume":"264","author":"Poole","year":"1993","journal-title":"Am. J. Physiol."},{"issue":"7","key":"10.1016\/j.canlet.2022.216043_bib57","doi-asserted-by":"crossref","first-page":"10248","DOI":"10.1002\/jcp.27694","article-title":"Ecto-5\u2019-nucleotidase (CD73) is a potential target of hepatocellular carcinoma","volume":"234","author":"Shali","year":"2019","journal-title":"J.\u00a0Cell. Physiol."},{"issue":"45","key":"10.1016\/j.canlet.2022.216043_bib58","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1038\/s41388-018-0379-9","article-title":"Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway","volume":"37","author":"Li","year":"2018","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.canlet.2022.216043_bib59","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1158\/1078-0432.CCR-18-0205","article-title":"Cancer-associated fibroblasts affect intratumoral CD8(+) and FoxP3(+) T cells via IL6 in the tumor microenvironment","volume":"24","author":"Kato","year":"2018","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"issue":"11","key":"10.1016\/j.canlet.2022.216043_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120631","article-title":"Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy","volume":"3","author":"Gyori","year":"2018","journal-title":"JCI insight"},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib61","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1435250","article-title":"NF-\u03baB RelA renders tumor-associated macrophages resistant to and capable of directly suppressing CD8(+) T cells for tumor promotion","volume":"7","author":"Li","year":"2018","journal-title":"OncoImmunology"},{"issue":"3","key":"10.1016\/j.canlet.2022.216043_bib62","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neo.2019.01.005","article-title":"Prognostic value of macrophage phenotypes in resectable non-small cell lung cancer assessed by multiplex immunohistochemistry","volume":"21","author":"Rakaee","year":"2019","journal-title":"Neoplasia"},{"issue":"7693","key":"10.1016\/j.canlet.2022.216043_bib63","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.canlet.2022.216043_bib64","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41419-018-0796-2","article-title":"CCL5-deficiency enhances intratumoral infiltration of CD8(+) T cells in colorectal cancer","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib65","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s40425-019-0697-7","article-title":"Natural killer T cell activation increases iNOS(+)CD206(-) M1 macrophage and controls the growth of solid tumor","volume":"7","author":"Paul","year":"2019","journal-title":"J\u00a0Immunother cancer"},{"issue":"8","key":"10.1016\/j.canlet.2022.216043_bib66","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1338239","article-title":"EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity","volume":"6","author":"Albu","year":"2017","journal-title":"OncoImmunology"},{"issue":"11","key":"10.1016\/j.canlet.2022.216043_bib67","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s00018-017-2720-9","article-title":"Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma","volume":"75","author":"Chen","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.canlet.2022.216043_bib68","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1158\/1078-0432.CCR-17-3852","article-title":"SMAC mimetic debio 1143 and ablative radiation therapy synergize to enhance antitumor immunity against lung cancer","volume":"25","author":"Tao","year":"2019","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"issue":"11","key":"10.1016\/j.canlet.2022.216043_bib69","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/2326-6066.CIR-17-0143","article-title":"PI3K\u03b3 activates integrin \u03b1(4) and promotes immune suppressive myeloid cell polarization during tumor progression","volume":"5","author":"Foubert","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib70","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/imr.12085","article-title":"Role of regulatory T cells during virus infection","volume":"255","author":"Veiga-Parga","year":"2013","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.canlet.2022.216043_bib71","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","article-title":"Human FOXP3(+) regulatory T cell heterogeneity and function in autoimmunity and cancer","volume":"50","author":"Wing","year":"2019","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib72","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s12885-019-5670-9","article-title":"Induction of tolerogenic dendritic cells by activated TGF-\u03b2\/Akt\/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells","volume":"19","author":"Zhong","year":"2019","journal-title":"BMC Cancer"},{"issue":"32","key":"10.1016\/j.canlet.2022.216043_bib73","doi-asserted-by":"crossref","first-page":"52294","DOI":"10.18632\/oncotarget.10561","article-title":"TGF-\u03b2 induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.canlet.2022.216043_bib74","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.4049\/jimmunol.174.9.5215","article-title":"TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells","volume":"174","author":"Ahmadzadeh","year":"2005","journal-title":"J.\u00a0Immunol."},{"issue":"12","key":"10.1016\/j.canlet.2022.216043_bib75","doi-asserted-by":"crossref","first-page":"7282","DOI":"10.4049\/jimmunol.166.12.7282","article-title":"A\u00a0role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood","volume":"166","author":"Yamagiwa","year":"2001","journal-title":"J.\u00a0Immunol."},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib76","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1053\/j.gastro.2019.01.261","article-title":"Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma","volume":"156","author":"Teufel","year":"2019","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib77","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.20082173","article-title":"Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1","volume":"206","author":"Kuang","year":"2009","journal-title":"J.\u00a0Exp. Med."},{"issue":"5","key":"10.1016\/j.canlet.2022.216043_bib78","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jhep.2012.12.015","article-title":"The functional impairment of HCC-infiltrating \u03b3\u03b4 T cells, partially mediated by regulatory T cells in a TGF\u03b2- and IL-10-dependent manner","volume":"58","author":"Yi","year":"2013","journal-title":"J.\u00a0Hepatol."},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib79","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbrc.2015.03.177","article-title":"Tumor-infiltrating lymphocyte activity is enhanced in tumors with low IL-10 production in HBV-induced hepatocellular carcinoma","volume":"461","author":"Shi","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib80","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.canlet.2022.216043_bib81","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85974","article-title":"TGF-\u03b2 and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies","volume":"1","author":"Courau","year":"2016","journal-title":"JCI insight"},{"issue":"12","key":"10.1016\/j.canlet.2022.216043_bib82","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1002\/ijc.28311","article-title":"Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments","volume":"133","author":"Lee","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"7511","key":"10.1016\/j.canlet.2022.216043_bib83","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/nature13554","article-title":"Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression","volume":"511","author":"Sandler","year":"2014","journal-title":"Nature"},{"issue":"6129","key":"10.1016\/j.canlet.2022.216043_bib84","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.1235214","article-title":"Persistent LCMV infection is controlled by blockade of type I interferon signaling","volume":"340","author":"Teijaro","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib85","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.canlet.2022.216043_bib86","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.4049\/jimmunol.180.7.4476","article-title":"Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways","volume":"180","author":"Jacobs","year":"2008","journal-title":"J.\u00a0Immunol."},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib87","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.canlet.2022.216043_bib88","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1101\/sqb.78.019869","article-title":"Programmed cell death 1-directed immunotherapy for enhancing T-cell function","volume":"78","author":"Araki","year":"2013","journal-title":"Cold Spring Harbor Symp. Quant. Biol."},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib89","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13567-018-0543-9","article-title":"Cooperation of PD-1 and LAG-3 in the exhaustion of CD4(+) and CD8(+) T cells during bovine leukemia virus infection","volume":"49","author":"Okagawa","year":"2018","journal-title":"Vet. Res."},{"issue":"2","key":"10.1016\/j.canlet.2022.216043_bib90","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1053\/j.gastro.2020.03.074","article-title":"Hepatocellular carcinoma cells up-regulate PVRL1, stabilizing PVR and inhibiting the cytotoxic T-cell response via TIGIT to mediate tumor resistance to PD1 inhibitors in mice","volume":"159","author":"Chiu","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib91","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.immuni.2012.08.021","article-title":"Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory","volume":"37","author":"Doering","year":"2012","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.canlet.2022.216043_bib92","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/ni.2714","article-title":"Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen","volume":"14","author":"Doedens","year":"2013","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.canlet.2022.216043_bib93","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.immuni.2014.10.013","article-title":"The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection","volume":"41","author":"Staron","year":"2014","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.canlet.2022.216043_bib94","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.immuni.2014.08.012","article-title":"Transforming growth factor \u03b2-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression","volume":"41","author":"Stephen","year":"2014","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.canlet.2022.216043_bib95","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1084\/jem.20070841","article-title":"Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells","volume":"204","author":"Intlekofer","year":"2007","journal-title":"J.\u00a0Exp. Med."},{"issue":"6111","key":"10.1016\/j.canlet.2022.216043_bib96","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.1229620","article-title":"Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection","volume":"338","author":"Paley","year":"2012","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.canlet.2022.216043_bib97","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1189\/jlb.0812400","article-title":"Technical Advance: fluorescent reporter reveals insights into eomesodermin biology in cytotoxic lymphocytes","volume":"93","author":"Paley","year":"2013","journal-title":"J.\u00a0Leukoc. Biol."},{"issue":"6316","key":"10.1016\/j.canlet.2022.216043_bib98","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"issue":"7749","key":"10.1016\/j.canlet.2022.216043_bib99","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"issue":"6316","key":"10.1016\/j.canlet.2022.216043_bib100","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T cell exhaustion","volume":"354","author":"Sen","year":"2016","journal-title":"Science"},{"issue":"7764","key":"10.1016\/j.canlet.2022.216043_bib101","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.canlet.2022.216043_bib102","doi-asserted-by":"crossref","first-page":"923","DOI":"10.20892\/j.issn.2095-3941.2020.0338","article-title":"Exhausted T cells and epigenetic status","volume":"17","author":"Zeng","year":"2020","journal-title":"Cancer Biol Med"},{"issue":"7764","key":"10.1016\/j.canlet.2022.216043_bib103","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib104","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.immuni.2018.11.014","article-title":"Checkpoint blockade immunotherapy induces dynamic changes in PD-1(-)CD8(+) tumor-infiltrating T cells","volume":"50","author":"Kurtulus","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib105","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.immuni.2019.11.002","article-title":"Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1(+) stem-like CD8(+) T cells during chronic infection","volume":"51","author":"Hudson","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib106","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib107","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A\u00a0clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J.\u00a0Hepatol."},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib108","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jhep.2022.02.019","article-title":"PKC\u03b1\/ZFP64\/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma","volume":"77","author":"Wei","year":"2022","journal-title":"J.\u00a0Hepatol."},{"issue":"7","key":"10.1016\/j.canlet.2022.216043_bib109","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2022.216043_bib110","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.canlet.2022.216043_bib111","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/ijms18030645","article-title":"TIM-3 as a target for cancer immunotherapy and mechanisms of action","volume":"18","author":"Du","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"52","key":"10.1016\/j.canlet.2022.216043_bib112","doi-asserted-by":"crossref","first-page":"e5749","DOI":"10.1097\/MD.0000000000005749","article-title":"Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma","volume":"95","author":"Li","year":"2016","journal-title":"Medicine (Baltim.)"},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib113","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.canlet.2022.216043_bib114","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1053\/j.gastro.2017.06.017","article-title":"Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas","volume":"153","author":"Zhou","year":"2017","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib115","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.4049\/jimmunol.1602086","article-title":"Cutting edge: chromatin accessibility programs CD8 T cell memory","volume":"198","author":"Scharer","year":"2017","journal-title":"J.\u00a0Immunol."},{"issue":"2","key":"10.1016\/j.canlet.2022.216043_bib116","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The biology of cancer testis antigens: putative function, regulation and therapeutic potential","volume":"5","author":"Fratta","year":"2011","journal-title":"Mol Oncol"},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib117","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","article-title":"Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer","volume":"171","author":"Topper","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2022.216043_bib118","first-page":"29","article-title":"Augmenting antitumor immune responses with epigenetic modifying agents","volume":"6","author":"H\u00e9ninger","year":"2015","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib119","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1038\/s41598-017-02608-0","article-title":"Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma","volume":"7","author":"Ritter","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.canlet.2022.216043_bib120","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.cell.2015.10.020","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"164","author":"Chiappinelli","year":"2016","journal-title":"Cell"},{"issue":"6230","key":"10.1016\/j.canlet.2022.216043_bib121","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.canlet.2022.216043_bib122","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"38","key":"10.1016\/j.canlet.2022.216043_bib123","doi-asserted-by":"crossref","first-page":"41339","DOI":"10.18632\/oncotarget.5463","article-title":"A\u00a0phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma","volume":"6","author":"Jiang","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.canlet.2022.216043_bib124","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5045\/br.2015.50.3.126","article-title":"Cellular immunotherapy as a beacon of hope for hematological malignancies","volume":"50","author":"Lee","year":"2015","journal-title":"Blood Res"},{"key":"10.1016\/j.canlet.2022.216043_bib125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594271","article-title":"Chimeric antigen receptor T-cell therapy in glioblastoma: current and future","volume":"11","author":"Li","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2022.216043_bib126","first-page":"690","article-title":"Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma","volume":"7","author":"Jiang","year":"2016","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.canlet.2022.216043_bib127","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-Specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"399","key":"10.1016\/j.canlet.2022.216043_bib128","article-title":"A\u00a0single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.canlet.2022.216043_bib129","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-Specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol."},{"issue":"7786","key":"10.1016\/j.canlet.2022.216043_bib130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib131","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3390\/cells10061332","article-title":"Natural killer cells and T cells in hepatocellular carcinoma and viral hepatitis: current status and perspectives for future immunotherapeutic approaches","volume":"10","author":"Kalathil","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib132","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.3390\/cells9061485","article-title":"Engineering strategies to enhance TCR-based adoptive T cell therapy","volume":"9","author":"Rath","year":"2020","journal-title":"Cells"},{"issue":"197","key":"10.1016\/j.canlet.2022.216043_bib133","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"6589","key":"10.1016\/j.canlet.2022.216043_bib134","doi-asserted-by":"crossref","DOI":"10.1126\/science.abl5282","article-title":"Tuning T cell receptor sensitivity through catch bond engineering","volume":"376","author":"Zhao","year":"2022","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.canlet.2022.216043_bib135","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.canlet.2022.216043_bib136","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.4161\/21645515.2014.982996","article-title":"Tumor cell lysates as immunogenic sources for cancer vaccine design","volume":"10","author":"Gonz\u00e1lez","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"issue":"13","key":"10.1016\/j.canlet.2022.216043_bib137","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-11-3044","article-title":"Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival","volume":"18","author":"Sawada","year":"2012","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib138","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00262-015-1728-y","article-title":"Developments in cancer vaccines for hepatocellular carcinoma","volume":"65","author":"Buonaguro","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2022.216043_bib139","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev-med-042617-101816","article-title":"Harnessing tumor mutations for truly individualized cancer vaccines","volume":"70","author":"Vormehr","year":"2019","journal-title":"Annu. Rev. Med."},{"issue":"7662","key":"10.1016\/j.canlet.2022.216043_bib140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"issue":"7738","key":"10.1016\/j.canlet.2022.216043_bib141","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.canlet.2022.216043_bib142","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41573-019-0043-2","article-title":"Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles","volume":"18","author":"Vanpouille-Box","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.canlet.2022.216043_bib143","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1021\/acs.jmedchem.1c00179","article-title":"Structure-based design of highly potent toll-like receptor 7\/8 dual agonists for cancer immunotherapy","volume":"64","author":"Wang","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"issue":"565","key":"10.1016\/j.canlet.2022.216043_bib144","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0391","article-title":"Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors","volume":"12","author":"M\u00e1rquez-Rodas","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.canlet.2022.216043_bib145","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1078-0432.CCR-18-0469","article-title":"Intratumoral G100, a TLR4 agonist, induces antitumor immune responses and tumor regression in patients with merkel cell carcinoma","volume":"25","author":"Bhatia","year":"2019","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib146","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4049\/jimmunol.1601145","article-title":"Intratumoral delivery of immunotherapy-act locally, think globally","volume":"198","author":"Aznar","year":"2017","journal-title":"J.\u00a0Immunol."},{"issue":"3","key":"10.1016\/j.canlet.2022.216043_bib147","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib148","article-title":"Repurposing infectious disease vaccines for intratumoral immunotherapy","volume":"8","author":"Melero","year":"2020","journal-title":"J\u00a0Immunother cancer"},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib149","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41467-017-00627-z","article-title":"Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8(+) T cells","volume":"8","author":"Fehlings","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib150","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.canlet.2022.216043_bib151","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.canlet.2022.216043_bib152","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1158\/1078-0432.CCR-19-2931","article-title":"Compartmental analysis of T-cell clonal dynamics as a function of pathologic response to Neoadjuvant PD-1 blockade in resectable non-small cell lung cancer","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib153","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13046-018-0713-7","article-title":"Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer","volume":"37","author":"Liu","year":"2018","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2022.216043_bib154","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/1878-0261.12029","article-title":"T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer","volume":"11","author":"Liu","year":"2017","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib155","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41375-021-01301-6","article-title":"Targeting LAG3\/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma","volume":"36","author":"Bae","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.canlet.2022.216043_bib156","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.3390\/cancers13092112","article-title":"LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia","volume":"13","author":"Sordo-Bahamonde","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.canlet.2022.216043_bib157","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00262-018-2283-0","article-title":"Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model","volume":"68","author":"Llopiz","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"16","key":"10.1016\/j.canlet.2022.216043_bib158","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-15-2584","article-title":"HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma","volume":"22","author":"Zheng","year":"2016","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"issue":"2\u20133","key":"10.1016\/j.canlet.2022.216043_bib159","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0753-3322(93)90294-U","article-title":"A\u00a0feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients","volume":"47","author":"Sekine","year":"1993","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.canlet.2022.216043_bib160","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3892\/etm.2011.271","article-title":"Adoptive cellular therapy enhances the helper T cell response and reduces the number of regulatory T cells","volume":"2","author":"Ishikawa","year":"2011","journal-title":"Exp. Ther. Med."},{"issue":"3","key":"10.1016\/j.canlet.2022.216043_bib161","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2567.2008.02910.x","article-title":"Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell","volume":"126","author":"Linn","year":"2009","journal-title":"Immunology"},{"issue":"16","key":"10.1016\/j.canlet.2022.216043_bib162","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"11","key":"10.1016\/j.canlet.2022.216043_bib163","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2022.216043_bib164","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular Normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"issue":"26","key":"10.1016\/j.canlet.2022.216043_bib165","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.canlet.2022.216043_bib166","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/s41388-019-1072-3","article-title":"Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization","volume":"39","author":"Xu","year":"2020","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.canlet.2022.216043_bib167","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41590-019-0561-4","article-title":"Immunological impact of cell death signaling driven by radiation on the tumor microenvironment","volume":"21","author":"Rodriguez-Ruiz","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2022.216043_bib168","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.lungcan.2019.05.029","article-title":"Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis","volume":"134","author":"Dafni","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib169","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1873607","article-title":"Addition of anti-TIM3 or anti-TIGIT antibodies to anti-PD1 blockade augments human T cell adoptive cell transfer","volume":"10","author":"Martinez","year":"2021","journal-title":"OncoImmunology"},{"issue":"6371","key":"10.1016\/j.canlet.2022.216043_bib170","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"6382","key":"10.1016\/j.canlet.2022.216043_bib171","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1126\/science.aar6918","article-title":"The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies","volume":"359","author":"Zitvogel","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.canlet.2022.216043_bib172","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41375-018-0293-8","article-title":"Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation","volume":"33","author":"Blagitko-Dorfs","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.canlet.2022.216043_bib173","first-page":"7591","article-title":"Combined treatment with epigenetic agents enhances anti-tumor activity of T cells by upregulating the ACRBP expression in hepatocellular carcinoma","volume":"13","author":"Ge","year":"2021","journal-title":"Am J Transl Res"},{"issue":"1","key":"10.1016\/j.canlet.2022.216043_bib174","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1186\/s12885-019-5740-z","article-title":"Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data","volume":"19","author":"Yoon","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2022.216043_bib175","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fonc.2014.00145","article-title":"Chemotherapy and oncolytic virotherapy: advanced tactics in the war against cancer","volume":"4","author":"Nguyen","year":"2014","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2022.216043_bib176","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00262-015-1698-0","article-title":"Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model","volume":"64","author":"Tagliamonte","year":"2015","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522005304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522005304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:09:30Z","timestamp":1759594170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383522005304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":176,"alternative-id":["S0304383522005304"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2022.216043","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD8+ T cell exhaustion and cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2022.216043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216043"}}